(Q34668891)

3 August 2017

title

Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series (English)

1 reference

post-transplant lymphoproliferative disorder

3 August 2017

main subject

0 references

sirolimus

1 reference

inferred from title

kidney transplantation

1 reference

Farzaneh Ashrafi

1

1 reference

3 August 2017

Shahrzad Shahidi

series ordinal

2

1 reference

3 August 2017

Zeinab Ebrahimi

series ordinal

3

1 reference

3 August 2017

Mojgan Mortazavi

series ordinal

4

1 reference

3 August 2017

publication date

1 January 2015

1 reference

International journal of hematology-oncology and stem cell research

3 August 2017

published in

1 reference

3 August 2017

volume

9

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

26-32

1 reference

Incidence of malignancy after living kidney transplantation: a multicenter study from iran

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Conversion to rapamycin immunosuppression for malignancy after kidney transplantation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Rapamycin: clinical results and future opportunities

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Rapamycin in transplantation: a review of the evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Rapamycin may prevent post-transplant lymphoma

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4369231

Post-transplant lymphoproliferative disorder

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25802698

12 December 2020

inferred from PubMed ID database lookup

Post-transplant lymphoproliferative disorders

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25802698

12 December 2020

inferred from PubMed ID database lookup

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25802698

12 December 2020

inferred from PubMed ID database lookup

Identifiers

PMC publication ID

4369231

1 reference

3 August 2017

1 reference